Cargando…
Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents
Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 ye...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736591/ https://www.ncbi.nlm.nih.gov/pubmed/26880915 http://dx.doi.org/10.1155/2016/5872423 |
_version_ | 1782413313205862400 |
---|---|
author | Dos Santos-Júnior, Amilton Henriques, Taciane Barbosa de Mello, Maricilda Palandi Della Torre, Osmar Henrique Paes, Lúcia Arisaka Ferreira-Neto, Adriana Perez Sewaybricker, Letícia Esposito Fontana, Thiago Salum Celeri, Eloisa Helena Rubello Valler Guerra-Júnior, Gil Dalgalarrondo, Paulo |
author_facet | Dos Santos-Júnior, Amilton Henriques, Taciane Barbosa de Mello, Maricilda Palandi Della Torre, Osmar Henrique Paes, Lúcia Arisaka Ferreira-Neto, Adriana Perez Sewaybricker, Letícia Esposito Fontana, Thiago Salum Celeri, Eloisa Helena Rubello Valler Guerra-Júnior, Gil Dalgalarrondo, Paulo |
author_sort | Dos Santos-Júnior, Amilton |
collection | PubMed |
description | Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations. |
format | Online Article Text |
id | pubmed-4736591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-47365912016-02-15 Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents Dos Santos-Júnior, Amilton Henriques, Taciane Barbosa de Mello, Maricilda Palandi Della Torre, Osmar Henrique Paes, Lúcia Arisaka Ferreira-Neto, Adriana Perez Sewaybricker, Letícia Esposito Fontana, Thiago Salum Celeri, Eloisa Helena Rubello Valler Guerra-Júnior, Gil Dalgalarrondo, Paulo Int J Endocrinol Research Article Objective. To identify the frequency of obesity and metabolic complications in child and adolescent users of risperidone. Potential associations with clinical parameters and SNPs of the HTR2C, DRD2, LEP, LEPR, MC4R, and CYP2D6 genes were analyzed. Methods. Samples from 120 risperidone users (8–20 years old) were collected and SNPs were analyzed, alongside assessment of chronological and bone ages, prescribed and weight-adjusted doses, use of other psychotropic drugs, waist circumference, BMI z-scores, blood pressure, HOMA-IR index, fasting levels of serum glucose, insulin, cholesterol, triglycerides, transaminases, and leptin. Results. Thirty-two (26.7%) patients were overweight and 5 (4.2%) obese. Hypertension was recorded in 8 patients (6.7%), metabolic syndrome in 6 (5%), and increased waist circumference in 20 (16.7%). The HOMA-IR was high for 22 patients (18.3%), while total cholesterol and triglycerides were high in 20 (16.7%) and 41 (34.2%) patients, respectively. SNP associations were found for LEP, HTR2C, and CYP2D6 with BMI; CYP2D6 with blood pressure, ALT, and HOMA-IR; HTR2C and LEPR with leptin levels; MC4R and DRD2 with HOMA-IR; HTR2C with WC; and LEP with ALT. Conclusions. Although not higher than in the general pediatric population, a high frequency of patients was overweight/obese, with abnormalities in metabolic parameters and some pharmacogenetic associations. Hindawi Publishing Corporation 2016 2016-01-06 /pmc/articles/PMC4736591/ /pubmed/26880915 http://dx.doi.org/10.1155/2016/5872423 Text en Copyright © 2016 Amilton Dos Santos-Júnior et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Dos Santos-Júnior, Amilton Henriques, Taciane Barbosa de Mello, Maricilda Palandi Della Torre, Osmar Henrique Paes, Lúcia Arisaka Ferreira-Neto, Adriana Perez Sewaybricker, Letícia Esposito Fontana, Thiago Salum Celeri, Eloisa Helena Rubello Valler Guerra-Júnior, Gil Dalgalarrondo, Paulo Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
title | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
title_full | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
title_fullStr | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
title_full_unstemmed | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
title_short | Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents |
title_sort | pharmacogenetics of risperidone and cardiovascular risk in children and adolescents |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736591/ https://www.ncbi.nlm.nih.gov/pubmed/26880915 http://dx.doi.org/10.1155/2016/5872423 |
work_keys_str_mv | AT dossantosjunioramilton pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT henriquestacianebarbosa pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT demellomaricildapalandi pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT dellatorreosmarhenrique pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT paesluciaarisaka pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT ferreiranetoadrianaperez pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT sewaybrickerleticiaesposito pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT fontanathiagosalum pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT celerieloisahelenarubellovaller pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT guerrajuniorgil pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents AT dalgalarrondopaulo pharmacogeneticsofrisperidoneandcardiovascularriskinchildrenandadolescents |